Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
- PMID: 36017784
- PMCID: PMC9548934
- DOI: 10.1177/02698811221116926
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Abstract
Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Before psychedelics become registered medicines, it is important to know the full range of adverse events (AEs) for making balanced treatment decisions.
Objective: To systematically review the presence of AEs during and after administration of serotonergic psychedelics and 3,4-methyenedioxymethamphetamine (MDMA) in clinical studies.
Methods: We systematically searched PubMed, PsycINFO, Embase, and ClinicalTrials.gov for clinical trials with psychedelics since 2000 describing the results of quantitative and qualitative studies.
Results: We included 44 articles (34 quantitative + 10 qualitative), describing treatments with MDMA and serotonergic psychedelics (psilocybin, lysergic acid diethylamide, and ayahuasca) in 598 unique patients. In many studies, AEs were not systematically assessed. Despite this limitation, treatments seemed to be overall well tolerated. Nausea, headaches, and anxiety were commonly reported acute AEs across diagnoses and compounds. Late AEs included headaches (psilocybin, MDMA), fatigue, low mood, and anxiety (MDMA). One serious AE occurred during MDMA administration (increase in premature ventricular contractions requiring brief hospitalization); no other AEs required medical intervention. Qualitative studies suggested that psychologically challenging experiences may also be therapeutically beneficial. Except for ayahuasca, a large proportion of patients had prior experience with psychedelic drugs before entering studies.
Conclusions: AEs are poorly defined in the context of psychedelic treatments and are probably underreported in the literature due to study design (lack of systematic assessment of AEs) and sample selection. Acute challenging experiences may be therapeutically meaningful, but a better understanding of AEs in the context of psychedelic treatments requires systematic and detailed reporting.
Keywords: LSD; MDMA; Psychedelics; adverse effects; adverse events; ayahuasca; psilocybin.
Conflict of interest statement
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RS received a research grant from the Netherlands Organization Health Research and Development for a clinical study on oral esketamine, and is the co-investigator of a clinical study on psilocybin funded by Compass Pathways. He has also received an educational grant from Janssen, Pharmaceutical Companies of Johnson and Johnson, and honorarium from Clexio Biosciences. EV is the principal investigator of a clinical trial on MDMA funded by the Multidisciplinary Association for Psychedelic Studies. WvdB has been a consultant for Janssen Netherlands and is a member of the Scientific Advisory Board of Clearmind. JJB, BK and JK declare no conflicts of interest.
Similar articles
-
Psychedelics and Psychedelic-Assisted Psychotherapy.Am J Psychiatry. 2020 May 1;177(5):391-410. doi: 10.1176/appi.ajp.2019.19010035. Epub 2020 Feb 26. Am J Psychiatry. 2020. PMID: 32098487 Review.
-
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.Expert Rev Clin Pharmacol. 2018 Sep;11(9):889-902. doi: 10.1080/17512433.2018.1511424. Epub 2018 Aug 23. Expert Rev Clin Pharmacol. 2018. PMID: 30102078 Review.
-
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520. Molecules. 2022. PMID: 35458717 Free PMC article. Review.
-
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.Psychiatry Res. 2024 May;335:115886. doi: 10.1016/j.psychres.2024.115886. Epub 2024 Mar 28. Psychiatry Res. 2024. PMID: 38574699 Review.
-
[Efficacy of psychedelics in psychiatry, a systematic review of the literature].Encephale. 2021 Aug;47(4):376-387. doi: 10.1016/j.encep.2020.12.002. Epub 2021 Apr 20. Encephale. 2021. PMID: 33888297 French.
Cited by
-
Personality traits explain the relationship between psychedelic use and less depression in a comparative study.Sci Rep. 2024 May 3;14(1):10195. doi: 10.1038/s41598-024-60890-1. Sci Rep. 2024. PMID: 38702496 Free PMC article.
-
Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.J Eat Disord. 2024 Apr 24;12(1):49. doi: 10.1186/s40337-024-01005-z. J Eat Disord. 2024. PMID: 38659049 Free PMC article. Review.
-
Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis.Neuropsychopharmacology. 2024 Jul;49(8):1208-1226. doi: 10.1038/s41386-024-01865-8. Epub 2024 Apr 23. Neuropsychopharmacology. 2024. PMID: 38654146 Free PMC article.
-
Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?Eur Arch Psychiatry Clin Neurosci. 2024 Feb 27. doi: 10.1007/s00406-024-01770-7. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38411629 Review.
-
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.bioRxiv [Preprint]. 2024 May 15:2024.02.04.578811. doi: 10.1101/2024.02.04.578811. bioRxiv. 2024. PMID: 38352491 Free PMC article. Preprint.
References
-
- Aday JS, Heifets BD, Pratscher SD, et al.. (2022) Great expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology 239: 1989–2010. - PubMed
-
- Andersen KAA, Carhart-Harris R, Nutt DJ, et al.. (2020) Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand 2021 143: 101–118. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical